Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 2006 Aug;145(2):388. doi: 10.1111/j.1365-2249.2006.03164_2.x

Corrigendum

PMCID: PMC1809681

In [1], the primer sequences in Table 1 were printed in error over one line instead of two. The corrected Table 1 is printed below.

Table 1.

Primers data for analysed proteoglycans.

Gene Primer sequences Gene size (bp) Tan*/amplicon length (bp)
Glypican 1 CGATGACCACTTCCAGCACC   3 316 66°C
GCAGGCGCAGCTCTCTCGG 290
Glypican 2 ACTGGGACACGACCTGGA   1 040 60°C
CATTCTCTCCCTCTCAGCCC 263
Glypican 3 CCAAGAGGCCTTTGAAATTG > 20 000 60°C
TGACTGGAAACAGGCTGTCA 199
Glypican 4 AGTGTGGTCAGCGAACAGTG  14 915 60°C
GCGAGCCCAGAAGTCATTTA 270
Glypican 5 CACTTTTCTGCAGGCACTCA  35 048 60°C
GGCTTTGTGTGGGTGTTCTT 400
Glypican 6 CCAGGACCTCTTCACAGAGC > 20 000 60°C
TGGGCAGTACAGCATCTTCA 315
Syndecan 1 GCTCTGGCTCTGGCTGTGC  20 871 65°C
CTGTGTGGGGAGTGTGAAGG 500
Syndecan 2 AAGACATGTACCTTGACAACAGC  15 903 60°C
AACTCCACCAGCAATGACAG 379
Syndecan 3 CAACCAGACACAGCCAATGA   1 156 63°C
GACCAAGAAGGCAGCAAAGA 218
Syndecan 4 ACGATGAGGATGTAGTGGGG   8 508 55°C
GGGTTTCTTGCCCAGGTC 406
*

Tan: annealing temperature.

Not found in the same contig or BAC.

In [2], the headings of the last two columns of Table 2 were transposed in error. The corrected Table 2 is printed below.

Table 2.

Characteristics and treatment of patients with acute graft-versus-host disease (aGvHD).

Pa GvHD (global grade) Organ Treatment Infections before GvHD treatment Outcome T cell chimerism (%)b
1 II Skin, intestine PDN, Leukotac Staphylococcus epidermidis NR 100
2 II Skin, intestine PDN, Leukotac Noc PR  70
3 III Liver, intestine PDN, MMF, Leukotac, ATG Candida albicans, Streptococcus viridans NR 100
4 II Skin PDN No CR 100
5 II Skin, liver PDN Staphylococcus epidermidis CR 100
6 I Skin PDN Enterococcus faecium CR 100
7 I Skin CsA, PDN, MMF No CR 100
8 II Skin, liver PDN, Leukotac, ATG Staphylococcus aureus NR 100
9 II Skin, intestine PDN No CR 100

ATG: anti-thymocyte immunoglobulin; CR: complete response; CsA: cyclosporin A; MMF: micophenolate mophetil; NR: non-response; PDN: prednisone; PR: partial response;

a

patient number;

b

chimerism at the time of aGvHD;

c

without infections.

We apologize for these errors.

References

  • 1.Wegrowski Y, Milard A-L, Kotlarz G, Toulmonde E, Maquart F-X, Toulmonde E, Bernard J. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin Exp Immunol. 2006;144:485–93. doi: 10.1111/j.1365-2249.2006.03059.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Paz Morante M, Briones J, Canto E, et al. Activation-associated phenotype pf CD3+ T cells in acute graft-versus-host disease. Clin Exp Immunol. 2006;145:36–43. doi: 10.1111/j.1365-2249.2006.03104.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES